Brolucizumab

證據等級: L5

預測適應症: 4 個

One-Sentence Summary

Brolucizumab (brand name Beovu) is an anti-VEGF-A antibody fragment originally used via intravitreal injection for wet age-related macular degeneration (AMD). The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but this is a model-score-only prediction (L5) with 0 clinical trials and 0 publications, and the evidence pack itself flags the mechanistic link as biologically implausible — likely an embedding-similarity false positive.

Quick Overview

Item	Content
Original Indication	Wet age-related macular degeneration (AMD) — based on known drug profile; not documented in the Finland regulatory dataset provided
Predicted New Indication	Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
TxGNN Prediction Score	99.67%
Evidence Level	L5
Finland Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for brolucizumab is not available from DrugBank (blocking data gap). Based on known drug information, brolucizumab is a humanized single-chain antibody fragment (scFv) that inhibits VEGF-A, administered by intravitreal injection for wet AMD — its efficacy in that indication is well established.

The predicted new indication, however, is a nuclear-DNA-related mitochondrial oxidative phosphorylation disorder. There is no known biological pathway overlap between VEGF-A/angiogenesis signaling and mitochondrial energy metabolism. The evidence pack's own mechanistic analysis explicitly flags this: despite the high TxGNN score (99.67%), the rationale states the mechanistic relevance is "extremely low" and that this is likely a high-scoring but biologically unexplainable prediction — possibly a false positive driven by embedding similarity rather than genuine pharmacology.

Three lower-ranked candidates (esophageal varices with/without bleeding, exocrine pancreatic insufficiency) were also predicted with similarly high scores (~99.1%), but each carries its own weakness: brolucizumab's intravitreal-only route of administration is incompatible with systemic or GI exposure needed for those indications, and anti-VEGF agents carry a known bleeding-risk signal that runs counter to a "with bleeding" varices indication. None of the four candidates currently has a defensible mechanistic case.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

No marketing authorizations are currently registered for brolucizumab in Finland (market status: 未上市 / not marketed; total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction has no known mechanistic pathway overlap with brolucizumab's anti-VEGF-A activity, zero supporting clinical trials or literature, and is explicitly flagged in the evidence pack as a likely embedding-driven false positive. Combined with the drug's non-marketed status in Finland, there is currently no basis to advance this candidate.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — currently a blocking data gap (DG001)
DrugBank mechanism-of-action detail (DG002)
An independent biological-plausibility review of the mitochondrial-disorder prediction, or re-evaluation of lower-score but mechanistically coherent candidates
If the esophageal-varices signal is pursued instead, a feasibility assessment of systemic/GI drug exposure given brolucizumab's intravitreal-only administration route
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.